CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published ahead of print on January 17, 2007
Clin J Am Soc Nephrol 2: 356-365, 2007
© 2007 American Society of Nephrology
doi: 10.2215/CJN.03280906

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
CJN.03280906v1
2/2/356    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jo, S. K.
Right arrow Articles by Okusa, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jo, S. K.
Right arrow Articles by Okusa, M. D.

Mini-Reviews

Pharmacologic Treatment of Acute Kidney Injury: Why Drugs Haven’t Worked and What Is on the Horizon

Sang Kyung Jo, Mitchell H. Rosner, and Mark D. Okusa

Department of Medicine, University of Virginia, Charlottesville, Virginia

Address correspondence to: Dr. Mark D. Okusa, Division of Nephrology, Box 800133, University of Virginia Health System, Charlottesville, VA 22908. Phone: 434-924-2187; Fax: 434-924-5848; E-mail: mdo7y{at}virginia.edu

Current strategies to limit the extent of injury in acute renal failure are based on extensive studies that identified cellular and molecular mechanisms of acute kidney injury. Despite successes in various animal models, translation to human studies has failed or studies are inconclusive. This review describes past failures and barriers to successful clinical trials. It also focuses on promising preclinical studies using novel compounds that currently are in or close to human investigation. Implementation of previous or novel compounds in well-designed clinical trials provides hope for the successful treatment of this devastating disorder.




This article has been cited by other articles:


Home page
CJASNHome page
M. Bennett, C. L. Dent, Q. Ma, S. Dastrala, F. Grenier, R. Workman, H. Syed, S. Ali, J. Barasch, and P. Devarajan
Urine NGAL Predicts Severity of Acute Kidney Injury After Cardiac Surgery: A Prospective Study
Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 665 - 673.
[Abstract] [Full Text] [PDF]


Home page
J Intensive Care MedHome page
M. H. Rosner, D. Portilla, and M. D. Okusa
Analytic Reviews: Cardiac Surgery as a Cause of Acute Kidney Injury: Pathogenesis and Potential Therapies
J Intensive Care Med, January 1, 2008; 23(1): 3 - 18.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society of Nephrology.